Skip to main content
OpenTrials

Clinical trial condition

Ovarian Diseases

Explore clinical trials studying Ovarian Diseases. Study availability and eligibility vary by location and protocol.

3,397 public trials 657 recruiting studies
Refine in advanced search Browse all conditions

Ovarian Diseases trial results

Active, Not Recruiting

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02595892

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +18 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • UC San Diego Medical Center - Hillcrest San Diego, California, United States
View all 17 locations
View Trial Details
Active, Not Recruiting

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02627443

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +26 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • UF Health Cancer Institute - Gainesville Gainesville, Florida, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02839707

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +33 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 920 locations
View Trial Details
Active, Not Recruiting

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02101775

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +33 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Decatur Memorial Hospital Decatur, Illinois, United States
View all 16 locations
View Trial Details
Active, Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Lymphoma, +138 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Thomas Hospital Fairhope, Alabama, United States
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
View all 1411 locations
View Trial Details
Active, Not Recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02446600

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +27 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
View all 356 locations
View Trial Details
Active, Not Recruiting

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

NCT05554328

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +21 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
View all 296 locations
View Trial Details

Related conditions